TAG: Vaccins

COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans. Laniece Delaunay C, et al, JAMA Netw Open 2024.	21 Apr 2025 à 04:07 -- Mon Apr 21 04:07:09 2025
Differences in characteristics and outcomes of older patients hospitalized for COVID-19 after introduction of vaccination. Smits RAL, et al, Eur Geriatr Med 2024.	01 Feb 2025 à 04:07 -- Sat Feb 1 04:07:12 2025
Effect of physical exercise on inactivated COVID-19 vaccine antibody response in the elderly. Şevgin Ö, et al, Hum Antibodies 2024.	13 Jul 2024 à 04:07 -- Sat Jul 13 04:07:23 2024
Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysis. Li Z, et al, Front Immunol 2022.	22 Sep 2025 à 04:07 -- Mon Sep 22 04:07:08 2025
Immunogenicity and Reactogenicity of Messenger RNA Coronavirus Disease 2019 Vaccine Booster Administered by Intradermal or Intramuscular Route in Thai Older Adults. Assantachai P, et al, J Infect Dis 2023.	08 Jan 2024 à 04:07 -- Mon Jan 8 04:07:07 2024
Immunogenicity, effectiveness and safety of COVID-19 vaccine in older adults living in nursing homes: A real-life study. Meijide Míguez H, et al, Rev Esp Geriatr Gerontol 2023.	02 May 2025 à 04:07 -- Fri May 2 04:07:11 2025
Influence of grandchildren on COVID-19 vaccination uptake among older adults in China: a parallel-group, cluster-randomized controlled trial. Bian J, et al, Nat Aging 2024.	21 May 2025 à 07:07 -- Wed May 21 07:07:13 2025
No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial. Naficy A, et al, Clin Infect Dis 2023.	15 Dec 2023 à 04:07 -- Fri Dec 15 04:07:09 2023
Protecting Nursing Homes and Long-Term Care Facilities From COVID-19: A Rapid Review of International Evidence. Dykgraaf SH, et al, J Am Med Dir Assoc 2021.	19 Jun 2023 à 22:49 -- Mon Jun 19 22:49:55 2023
Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older. Chen Y, et al, Expert Rev Vaccines 2023.	27 Mar 2024 à 07:07 -- Wed Mar 27 07:07:13 2024